IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, announced net loss of $32.64 million or $0.52 per share, wider than $23.07 million or $0.50 per share in the prior-year quarter.
Collaboration revenues for the quarter declined to $3.92 million from $4.02 million in the same quarter last year.
On average, ten analysts polled by Thomson Reuters expected the company to report a loss of $0.47 per share on revenues of $8.84 million for the quarter. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.